ArticleBMC infectious diseases2025
Characterization of Plasmodium falciparum infections among people living with HIV under antiretroviral and co-trimoxazole chemoprophylaxis in Brazzaville, Republic of Congo.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reversal of Chloroquine Resistance inInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlthough interactions between human immunodeficiency virus (HIV) and Plasmodium falciparum infections may lead to an exponential rise in their harmful impact on human health, few data exist on the prevalence of Plamodium species, the multiplicity of infection and molecular markers of antimalarial drug resistance, as well as clinical presentation of malaria infections in Congolese people living with HIV (PLWH). The aim of this study was to characterize malaria infection among PLWH receiving antiretroviral treatment (ART) and co-trimoxazole prophylaxis in Brazzaville, Republic of Congo.
methodAs part of follow-up activities, blood samples, socio-demographic and clinical data were collected from 683 PLWH aged from 1 month to 84 years (sex ratio male/female of 0.4) under ART and co-trimoxazole prophylaxis. This heath facility-based cross-sectional study was conducted from January to September 2022 at the Outpatient Treatment Center of the National HIV Program, located in Brazzaville. Malaria infection was diagnosed by microscopy and nested PCR. Single nucleotide polymorphisms (SNP) were detected by RFLP-PCR for the Pfdhfr, Pfdhps, Pfcrt genes and by sequencing for the PfK13 and Pfmdr1 genes. Plasmodium falciparum genetic diversity was investigated by nested PCR using gene markers (msp1, msp2 and glurp).
resultsAll the Plasmodium infected participants were asymptomatic. By microscopy, 1.2% (8/683) were found to be infected, whereas 9.2% (62/675) carried submicroscopic infections detected by PCR. P. falciparum mono-infection was the most common (69/70, 98.6%), but single separate cases of P. malariae alone, and of co-infection, P. falciparum with P. ovale, were also detected. The mean multiplicity of P. falciparum infection was 2.1 ± 1.09, with 68.1% of infections being polyclonal. Overall, a high prevalence of mutations was found within the Pfdhfr gene: 51I (78.2%), 59R (84.2%), 108N (84.0%); Pfdhps gene: 437G (72.0%, 540E (30.8%), 581G (48.5%); Pfcrt gene: 76T (46.9%) and Pfmdr1gene: 184F (42.1%). None of the Pfmdr1 86Y, 1034C, 1042D, and 1246Y mutant alleles or of the 12 significant mutations known to confer artemisinin partial resistance, were detected.
conclusionThe results of this study show a very low prevalence of malaria infection and a comparatively low genetic diversity of P. falciparum in isolates from PLWH under antiretroviral therapy and co-trimoxazole-based chemoprophylaxis in Brazzaville.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.